8-K
filed May 12, 2026, 5:01 PM ET
ticker ABBV
CIK 0001551152
other material
confidence high
sentiment neutral
materiality 0.10
AbbVie shareholders re-elect all Class II directors; reject supermajority elimination and independent chair proposal
AbbVie Inc.
- All four Class II directors elected: Davis (1.22B for), Meyer (1.28B), Michael (1.22B), Waddell (1.23B).
- Ratification of EY as auditor approved with 1.52B votes for, 23.8M against.
- Advisory say-on-pay approved with 1.23B for, 69.3M against.
- Proposal to eliminate supermajority voting did not pass: 1.29B for (needed supermajority).
- Stockholder proposal for independent chair rejected: 515.6M for, 787.3M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AbbVie Inc. shareholders approved The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026 at the 2026-05-08 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows: For Against Abstain 1,522,575,012 23,766,564 2,136,457
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AbbVie Inc. shareholders rejected The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting at the 2026-05-08 meeting.
- Proposal
- charter amendment
- Outcome
- failed
- Meeting
- 2026-05-08
Exact text from the filing
The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows: For Against Abstain Broker Non-Votes 1,290,990,023 14,896,119 3,192,310 239,399,581
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AbbVie Inc. shareholders rejected The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair at the 2026-05-08 meeting.
- Outcome
- failed
- Meeting
- 2026-05-08
Exact text from the filing
The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows: For Against Abstain Broker Non-Votes 515,626,009 787,253,970 6,198,473 239,399,581
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AbbVie Inc. shareholders approved The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers at the 2026-05-08 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows: For Against Abstain Broker Non-Votes 1,228,615,745 69,336,359 11,126,348 239,399,581
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 1.0
AbbVie Inc. shareholders approved The stockholders elected AbbVie’s Class II directors with terms expiring in 2029 at the 2026-05-08 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-08
Exact text from the filing
The stockholders elected AbbVie’s Class II directors with terms expiring in 2029, as follows: Name For Against Abstain Broker Non-Votes Jennifer L. Davis 1,216,558,754 89,839,329 2,680,369 239,399,581 Melody B. Meyer 1,284,771,578 22,470,074 1,836,800 239,399,581 Robert A. Michael 1,221,224,370 85,865,852 1,988,230 239,399,581 Frederick H. Waddell 1,225,237,825 81,747,033 2,093,594 239,399,581
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.